Phase II study of cabazitaxel with or without abiraterone acetate and prednisone in patients with metastatic castrate resistant prostate cancer after prior docetaxel and abiraterone acetate.

Kessler, E R

Phase II study of cabazitaxel with or without abiraterone acetate and prednisone in patients with metastatic castrate resistant prostate cancer after prior docetaxel and abiraterone acetate. [electronic resource] - Annals of oncology : official journal of the European Society for Medical Oncology 03 2017 - 668 p. digital

Publication Type: Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Comment

1569-8041

10.1093/annonc/mdw674 doi


Abiraterone Acetate
Docetaxel
Humans
Male
Prednisone
Prostatic Neoplasms
Prostatic Neoplasms, Castration-Resistant
Taxoids